Search Videos by Topic or Participant
Browse by Series:

Case Study: Progression on ALK Inhibitors in NSCLC

Panelists: Corey J. Langer, MD, Penn Medicine; Roy S. Herbst, MD, PhD, Yale;Karen L. Reckamp, MD, MS, City of Hope; Anne S. Tsao, MD, MD Anderson
Published: Tuesday, Oct 01, 2013
For High-Definition, Click
In the continuation of a case-based discussion, moderator Corey J. Langer, MD, notes that a 46 year-old woman with ALK-positive NSCLC has progressed following 11 months on crizotinib. In general, the disease is stable with progression to only a single rib with increasing pain, Langer notes.

At this point, Karen L. Reckamp, MD, MS, recommends continuing treatment with crizotinib while treating the rib lesion with local therapy. This approach is effective for treating localized progression, including brain metastases. However, if a systemic progression became apparent, Reckamp would pursue a clinical trial investigating a second-generation ALK inhibitor.

The second-generation ALK inhibitors LDK378 and the AP26113 have both demonstrated activity in patients refractory to crizotinib, explains Roy S. Herbst, MD, PhD. Additionally, these agents seem to cross the blood-brain barrier and both are advancing rapidly through clinical trials. In the context of research, Herbst would rebiopsy patients following progression on targeted TKIs, to assess possible secondary mutations or marker changes.

If a clinical trial is not an option, cytotoxic chemotherapy remains an acceptable treatment options following progression on crizotinib. In many cases, Herbst believes, chemotherapy is underutilized in this setting causing these patients to be undertreated. In a patient with a good performance status and no access to a clinical trial, Herbst recommends single agent pemetrexed or carboplatin plus pemetrexed.
Slider Left
Slider Right
For High-Definition, Click
In the continuation of a case-based discussion, moderator Corey J. Langer, MD, notes that a 46 year-old woman with ALK-positive NSCLC has progressed following 11 months on crizotinib. In general, the disease is stable with progression to only a single rib with increasing pain, Langer notes.

At this point, Karen L. Reckamp, MD, MS, recommends continuing treatment with crizotinib while treating the rib lesion with local therapy. This approach is effective for treating localized progression, including brain metastases. However, if a systemic progression became apparent, Reckamp would pursue a clinical trial investigating a second-generation ALK inhibitor.

The second-generation ALK inhibitors LDK378 and the AP26113 have both demonstrated activity in patients refractory to crizotinib, explains Roy S. Herbst, MD, PhD. Additionally, these agents seem to cross the blood-brain barrier and both are advancing rapidly through clinical trials. In the context of research, Herbst would rebiopsy patients following progression on targeted TKIs, to assess possible secondary mutations or marker changes.

If a clinical trial is not an option, cytotoxic chemotherapy remains an acceptable treatment options following progression on crizotinib. In many cases, Herbst believes, chemotherapy is underutilized in this setting causing these patients to be undertreated. In a patient with a good performance status and no access to a clinical trial, Herbst recommends single agent pemetrexed or carboplatin plus pemetrexed.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x